TSX · ACB.TO
Aurora Cannabis Inc.
CA$5.74+CA$0.03 (+0.53%)
Aurora Cannabis Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.4% below the high.
Loading market information…
XETRA · B8FK.DE · EUR
Stock price, earnings
Quote as of Oct 30, 2026, 08:02 AM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Biofrontera AG’s quoted price sits in the lower half of its reported 52-week range, 43.24% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Biofrontera AG’s next earnings report is currently expected on Nov 19, 2026, with estimated earnings per share of -€1.10. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Biofrontera AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the United States, and other global markets. Its primary products include Ameluz and the BF-RhodoLED lamp, which are utilized for treating mild to moderate actinic keratoses on the face and scalp, addressing field cancerization, and managing fatal squamous cell carcinoma. The company also supplies the RhodoLED XL lamp, engineered for treating multiple interspersed lesions, alongside Belixos, a cosmetic range developed for irritated and sensitive skin. Biofrontera AG maintains a licensing and supply agreement with Maruho Co., Ltd. Founded in 1997, the company's corporate headquarters are situated in Leverkusen, Germany.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| €11.99M+40.83% vs estimate |
| Q1 2023 | May 31, 2023 | -€0.05+82.39% vs estimate | €5.80M-64.55% vs estimate |
|---|
| Q3 2022 | Nov 14, 2022 | -€0.09+94.19% vs estimate | €6.83M-24.99% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$5.74+CA$0.03 (+0.53%)
Aurora Cannabis Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.4% below the high.
$0.77-$0.16 (-16.89%)
Inovio Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.63% below the high.
€0.09€0.00 (0.0%)
Clovis Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.97% below the high.
€2.64-€0.16 (-5.71%)
ifa systems AG’s quoted price sits in the lower half of its reported 52-week range, 44.54% below the high.
€0.25€0.00 (0.0%)
co.don AG’s quoted price sits in the lower half of its reported 52-week range, 89.57% below the high.
€0.02€0.00 (0.0%)
BZAM Ltd.’s quoted price sits in the lower half of its reported 52-week range, 88.28% below the high.
€0.00+€0.00 (+14.29%)
High Fusion Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
Molecule Holdings Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
